Denosumab, sold under the brand name Prolia among others, is a human monoclonal antibody used for the treatment of osteoporosis, treatment-induced bone...
46 KB (4,317 words) - 20:33, 29 May 2025
denipride (INN) denopamine (INN) denosumab (INN) denosumab-bbdz Denosumab BBL denosumab-bmwo denosumab-bnht denosumab-dssb denotivir (INN) denpidazone...
14 KB (586 words) - 23:15, 2 May 2025
imperfecta to reduce the risk of broken bones. Combined teriparatide and denosumab increased BMD more than either agent alone and more than has been reported...
27 KB (2,031 words) - 22:20, 29 May 2025
rhabdomyolysis, tumor lysis syndrome, and medications such as bisphosphonates or denosumab. Diagnosis should generally be confirmed by determining the corrected...
19 KB (1,867 words) - 00:39, 3 January 2025
they shrink tumors. Other bone modifying agents like zoledronic acid and denosumab can reduce prostate cancer bone pain, even though they have little effect...
81 KB (9,190 words) - 21:59, 29 May 2025
60-90% of patients who were treated for hypercalcemia of malignancy. Denosumab is a bone anti-resorptive agent that can be used to treat hypercalcemia...
34 KB (3,301 words) - 21:18, 23 January 2025
and bone-targeting chemotherapeutic agents such as bisphosphonates and denosumab. Orthopedic interventions such as internal fixation or spinal decompression...
26 KB (2,714 words) - 01:26, 24 May 2025
incident occurring in 2003. Osteonecrotic complications associated with denosumab, another antiresorptive drug from a different drug category, were soon...
46 KB (4,900 words) - 21:27, 29 May 2025
disparities exist. She has also appeared in commercials for Prolia, a brand of denosumab used in the treatment of osteoporosis. Danner was married to producer...
34 KB (1,707 words) - 00:05, 31 May 2025
medicamentosa. Denosumab inhibits osteoclast recycling, which results in the accumulation of pre-osteoclasts and osteomorphs. When denosumab therapy is discontinued...
12 KB (1,355 words) - 12:47, 25 May 2025
relating to the US Food and Drug Administration (FDA)-approved Sandoz denosumab biosimilars. In November 2024, Sandoz inaugurated the new headquarters...
37 KB (2,973 words) - 15:52, 3 May 2025
metastases benefit from regular infusion of the bone-strengthening agents denosumab and the bisphosphonates; infusion every three months reduces the chance...
140 KB (15,802 words) - 18:23, 23 May 2025
adalimumab/Humira March 2024 denosumab-bbdz/Jubbonti denosumab/Prolia March 2024 denosumab-bbdz/Wyost denosumab/Xgeva March 2024 tocilizumab-aazg/Tyenne...
103 KB (7,226 words) - 20:09, 29 May 2025
it is no longer believed that they prevent progression of the disease. Denosumab has been found successful in reducing bone pain and decreasing tumor growth...
22 KB (2,352 words) - 18:30, 22 May 2025
PMID 25729036. S2CID 43537545. Chiu YG, Ritchlin CT (January 2017). "Denosumab: targeting the RANKL pathway to treat rheumatoid arthritis". Expert Opinion...
158 KB (17,076 words) - 13:54, 22 May 2025
PMID 24063695. S2CID 20163452. Gauthier K, Bai A, Perras C, et al. (2012). "Denosumab, Raloxifene, and Zoledronic Acid for the Treatment of Postmenopausal Osteoporosis:...
100 KB (9,760 words) - 21:29, 29 May 2025
tested in conjunction with calcium and vitamin D to encourage bone health. Denosumab, a monoclonal antibody treatment RANKl inhibitor that targets the osteocyte...
6 KB (673 words) - 01:12, 6 January 2025
Dulanermin Antibodies: Belimumab Brentuximab vedotin Conatumumab Dacetuzumab Denosumab Drozitumab Enavatuzumab Iratumumab Lexatumumab Lucatumumab Mapatumumab...
49 KB (6,227 words) - 17:23, 29 April 2025
breast cancer, it increases the risk of blood clots and strokes. While denosumab is effective at preventing fractures in women, there is not clear evidence...
143 KB (16,154 words) - 21:46, 29 May 2025
one year, and the benefit was maintained after a second year of taking denosumab. In the other, one year of romosozumab followed by one year of alendronate...
13 KB (934 words) - 22:06, 29 May 2025
C; Cunningham, J; Ahuja, T; Richter, T; Kovacs, C (February 2012). "Denosumab, Raloxifene, and Zoledronic Acid for the Treatment of Postmenopausal Osteoporosis:...
32 KB (3,632 words) - 20:09, 29 May 2025
is a brand name of a biosimilar for the monoclonal antibody medication denosumab. This page lists people with the surname Junod. If an internal link intending...
642 bytes (101 words) - 21:32, 2 May 2025
Optimal treatment for this condition is unclear. Bisphosphonates and denosumab may be of use for the bone lesions. Cyclosporine A may be of use for treating...
5 KB (518 words) - 20:18, 17 May 2023
avenue of development for strategies targeting NF-κB inhibition. The drug denosumab acts to raise bone mineral density and reduce fracture rates in many patient...
90 KB (9,838 words) - 00:45, 26 May 2025
(2017-06-01). "FRI0568 Echosound approach for short-term follow-up of the denosumab effect on bmd recovery against aromatase inhibitor impact in breast cancer...
20 KB (2,133 words) - 05:45, 23 May 2025
osteoporosis such as estrogen replacement therapy, bisphosphonates or denosumab and for treatment hypercalciuria to reduce the risk for kidney stones...
23 KB (2,503 words) - 06:22, 26 May 2025
(FDA approved 2008) Otezla (apremilast) Parsabiv (etelcalcetide) Prolia (denosumab) for postmenopausal osteoporosis Repatha (evolocumab) Riabni (rituximab-arrx)...
102 KB (8,229 words) - 19:55, 29 May 2025
Dulanermin Antibodies: Belimumab Brentuximab vedotin Conatumumab Dacetuzumab Denosumab Drozitumab Enavatuzumab Iratumumab Lexatumumab Lucatumumab Mapatumumab...
24 KB (2,769 words) - 05:48, 21 May 2025
Pharmaceutical, Hetero Drugs, Roche Influenza Oct-1999 Mon-20XX 91 Xgeva Denosumab 197,711 3.24% Amgen Osteoporosis Nov-2010 Mon-20XX 92 Evista Raloxifene...
29 KB (289 words) - 21:21, 29 May 2025